Abstract
Down syndrome (DS) is caused by the trisomy of human chromosome 21 (HSA21). A major challenge in DS research is to identify the HSA21 genes that cause specific symptoms. Down syndrome cell adhesion molecule (DSCAM) is encoded by a HSA21 gene. Previous studies have shown that the protein level of the Drosophila homolog of DSCAM determines the size of presynaptic terminals. However, whether the triplication of DSCAM contributes to presynaptic development in DS remains unknown. Here, we show that DSCAM levels regulate GABAergic synapses formed on neocortical pyramidal neurons (PyNs). In the Ts65Dn mouse model for DS, where DSCAM is overexpressed due to DSCAM triplication, GABAergic innervation of PyNs by basket and chandelier interneurons is increased. Genetic normalization of DSCAM expression rescues the excessive GABAergic innervations and the increased inhibition of PyNs. Conversely, loss of DSCAM impairs GABAergic synapse development and function. These findings demonstrate excessive GABAergic innervation and synaptic transmission in the neocortex of DS mouse models and identify DSCAM overexpression as the cause. They also implicate dysregulated DSCAM levels as a potential pathogenic driver in related neurological disorders.
Developmental brain disorders are a hallmark of Down syndrome, but what cellular and molecular mechanisms underlie these disorders? This study shows that the excessive number of inhibitory synapses in the neocortex of Down syndrome mouse models is caused by increased levels of Down Syndrome Cell Adhesion Molecule (DSCAM).
Introduction
Down syndrome (DS) is caused by an extra copy of human chromosome 21 (HSA21), and people with DS exhibit a number of medical conditions. A major challenge in DS research is to identify the genes on HSA21 that cause specific cellular and system alterations leading to the symptoms. Down syndrome cell adhesion molecule (DSCAM) is an evolutionarily conserved type I transmembrane protein encoded by a HSA21 gene [1]. In humans, the DSCAM gene resides in the DS critical region of HSA21 [1], which is associated with many symptoms of DS. We previously showed that protein levels of the Drosophila homolog of DSCAM, Dscam [2], determine the sizes of presynaptic terminals in sensory neurons without requiring the ectodomain diversity of the Drosophila Dscam gene [3]. Moreover, others reported that overexpression of Dscam impairs synaptic targeting and transmission in Drosophila [4,5]. These findings suggest that dysregulated DSCAM levels might contribute to neuronal defects in brain disorders in humans. In fact, altered DSCAM levels have been reported in multiple brain disorders, including DS [6], autism spectrum disorders (ASDs) [7–9], intractable epilepsy [10], bipolar disorder [11], and possibly Fragile X syndrome [3,4,12,13]. Although recent findings suggest a conserved role of DSCAM in promoting presynaptic growth in vertebrates [14,15], whether dysregulated DSCAM expression results in neuronal defects in brain disorders remains to be empirically determined.
In this work, we sought to determine the effects of altered DSCAM levels in mouse models of DS, in which the DSCAM gene is triplicated. Previous studies have shown that enhanced GABAergic inhibition impairs cognition in Ts65Dn mice [16–20], the most widely used DS animal model [21,22]. Furthermore, Ts65Dn mice show excessive GABAergic inhibition in the hippocampus [16,23–31]. Overproduction of GABAergic neurons caused by triplication of Olig1 and Olig2 contributes to excessive inhibition in the hippocampus [29–31]. However, several lines of evidence suggest heterogeneous etiology in DS brain disorders such that different brain regions exhibit distinct molecular, cellular, and physiological defects. For example, the frequency of miniature inhibitory postsynaptic currents (mIPSCs) is increased in the dentate gyrus, but not the CA1 region, of the hippocampus in Ts65Dn mice [25,31]. In contrast to extensive reports on GABAergic deficits in the hippocampus of DS animal models, very little is known about whether GABAergic signaling is altered in the neocortex. Previous studies showed that the sizes of inhibitory synaptic boutons are enlarged in the neocortex of Ts65Dn mice, suggesting possible alterations in GABAergic synaptic functions in this region [32,33]. In the present study, we show excessive GABAergic innervation of and synaptic transmission to neocortical pyramidal neurons (PyNs) in Ts65Dn and demonstrate that DSCAM overexpression in GABAergic neurons plays a key role in this process.
By combining genetic tools for sparse labeling and whole-cell patch-clamp recording, we found excessive GABAergic innervation and inhibition of cortical PyNs by chandelier cells (ChC) and basket cells in Ts65Dn mice. Genetic normalization of DSCAM levels rescued presynaptic overgrowth and excessive synaptic transmission of GABAergic neurons. Consistently, loss of DSCAM impaired ChC presynaptic growth and reduced inhibition of PyNs. In addition, we found that ChC axon terminal growth and bouton number are coupled and positively correlated with DSCAM levels in both wild-type and Ts65Dn mice. These findings thus highlight the critical role of DSCAM levels in regulating GABAergic synapses in the neocortex. Therefore, dysregulated DSCAM expression levels may be a common contributor to GABAergic dysfunctions in associated neurological diseases.
Results
DSCAM overexpression in Ts65Dn mice increases the number of GABAergic boutons on PyN somas in the neocortex
DSCAM is overexpressed in the brains of DS patients [6]. We found that it is also overexpressed in the Ts65Dn mouse (Fig 1A), a widely used DS model in which DSCAM is present in 3 copies [21]. Previous studies in Ts65Dn neocortices have demonstrated increased numbers of GABAergic synapses [34] and enlargement of these synapses [32,33], but which HSA21 gene(s) causes changes in GABAergic synapses is poorly understood. DSCAM is expressed in GABAergic neurons [35]. Thus, we asked whether GABAergic synapse number is altered in the Ts65Dn mice and, if it is, whether DSCAM is responsible.
Crossing female Ts65Dn mice with the male loss-of-function mutant of a gene of interest (e.g., DSCAM) yields trisomic mice with 2 functional copies of that gene. If heterozygous mutant is used, the progeny also includes the regular trisomic and euploid littermates (Fig 1B). As such, the contribution of a specific gene that is triplicated in Ts65Dn mice can be determined by comparing the mice that are “normalized” for the gene of interest with the trisomic mice [31,36]. To test the effects of DSCAM triplication by using this genetic scheme, we used a protein-null allele DSCAM2j [37–39] (referred to as DSCAM−/− here on). In Ts65Dn mice normalized for DSCAM gene dosage (Ts65Dn:DSCAM+/+/− genotype), the average level of DSCAM proteins were statistically indistinguishable from the euploid mice (Fig 1A). As a control, normalizing DSCAM gene dosage did not change the increased level of amyloid precursor protein (APP) in Ts65Dn (S1A Fig), which is encoded by another HSA21 gene that is important for brain disorders of DS [36].
Basket cells are the most common cortical interneurons that preferentially innervate the soma and proximal dendrites of PyNs [40,41]. We analyzed the GABAergic boutons formed on PyN soma (i.e., perisomatic boutons)—which are predominantly formed by basket cells—in cortical layer II/III of the anterior cingulate cortex (ACC) on postnatal day 28 (P28), a time after basket cell development is largely complete [42]. To visualize perisomatic GABAergic boutons, brain sections were triply labeled with anti-Bassoon (for presynaptic active zone) [43], anti-VGAT (for presynaptic GABAergic boutons) [44], and anti-GRASP1 (for PyN soma and proximal dendrites) [45]. We determined whether the number of GABAergic boutons around each PyN soma—as indicated by Bassoon+ puncta that overlapped with VGAT+ signals (S1B Fig)—was changed by the loss of DSCAM gene. Quantification was performed in a double-blind fashion to avoid experimenter bias.
Consistent with previous reports [33,34], we found that the average number of GABAergic boutons around each PyN soma was significantly increased in Ts65Dn in both ACC (Fig 1C and 1E) and the somatosensory cortex (S2 Fig). Strikingly, normalizing DSCAM expression level completely rescued the increased number of boutons. Average soma size of PyNs was not affected in Ts65Dn or Ts65Dn:DSCAM+/+/− mice (S1D Fig). These data suggest that the DSCAM overexpression in Ts65Dn mice increases the number of GABAergic boutons on PyN somas.
DSCAM is expressed in GABAergic neurons [35]. Next, we determined whether the extra copy of DSCAM gene within GABAergic neurons leads to the excessive GABAergic boutons on PyN soma. Previous studies in Drosophila sensory neurons [3] and mouse retinal ganglion cells [15] suggest a cell-autonomous role of DSCAM in promoting axonal growth. To address this question, we took advantage of Lhx6-Cre mouse line, which targets GABAergic interneurons, including basket and ChC cells, at early developmental stages [46,47]. Crossing Lhx6-Cre mice with mice carrying a floxed DSCAM allele (DSCAMflox) [48] in the Ts65Dn background leads to the normalization of DSCAM gene expression specifically in GABAergic neurons. Normalizing DSCAM dosage in GABAergic neurons reduced the number of perisomatic GABAergic boutons to the euploid level (Fig 1D and 1F). These results suggest that the extra copy of DSCAM in GABAergic neurons leads to the excessive GABAergic boutons on PyN somas.
Normalizing DSCAM levels rescues the excessive GABAergic synaptic transmission in the Ts65Dn neocortex
Despite previous reports of increased numbers and enlargement of GABAergic synapses in Ts65Dn neocortices [32–34], whether GABAergic synaptic transmission in the neocortex is increased in these mice remains to be determined. Our finding that the overexpressed DSCAM in Ts65Dn mice increased GABAergic boutons in the neocortex prompted us to test this possibility.
We examined GABAergic synaptic transmission in acute neocortical slices, using the whole-cell patch-clamp to record from PyNs in layers II/III of the ACC. We found that mIPSC frequency was increased by approximately 63% in Ts65Dn mice compared to euploid littermates (Fig 2A and 2B), which is consistent with increased bouton numbers in basket cells (Fig 1C and 1E). By contrast, we found no difference in mIPSC amplitudes between euploid littermates and Ts65Dn mice (Fig 2A and 2C), suggesting that postsynaptic responses may not be affected by the trisomy. Consistent with the role of DSCAM in the increased number of GABAergic boutons in Ts65Dn mice (Fig 1C and 1E), normalizing DSCAM expression prevented the increase in mIPSC frequency in these mice (Fig 2A and 2B), suggesting that DSCAM overexpression causes excessive GABAergic synaptic transmission. Similar changes in the frequency, but not the amplitude, were observed in spontaneous inhibitory postsynaptic currents (sIPSCs) among euploid, Ts65Dn, and Ts65Dn:DSCAM+/+/− mice (S3 Fig), consistent with increased GABA synaptic sites.
The resting potential, threshold, and action potential amplitude of PyNs were indistinguishable among euploid, Ts65Dn, and Ts65Dn:DSCAM+/+/− mice (S4A–S4C Fig). We observed a subtle difference in the action potential half-width between Ts65Dn and euploid (S4D Fig); however, this slight change did not affect the depolarization and repolarization velocities (dv/dt) (S4E and S4F Fig), which were not different among the 3 groups. These results suggest that the membrane properties of PyNs are not affected by trisomy or trisomy with 2 copies of DSCAM. Moreover, the firing frequencies and rheobase (defined as the minimal current required to evoke an action potential) were indistinguishable among euploid, Ts65Dn, and Ts65Dn:DSCAM+/+/− mice (S4G and S4H Fig). This suggests that the excitability of PyNs is largely unaffected by the trisomy or trisomy with 2 copies of DSCAM.
We further determined whether normalizing DSCAM dosage specifically in GABAergic neurons rescues the increased frequencies of mIPSC seen in the Ts65Dn neocortex. Lhx6-Cre mice were crossed with DSCAMflox mice to generate Lhx6-Cre:DSCAMflox mice in the Ts65Dn background (Ts65Dn:Lhx6-Cre:DSCAMflox). Normalizing DSCAM dosage in GABAergic neurons in Ts65Dn mice completely rescued mIPSC frequencies to the euploid level (Fig 2D and 2E). The amplitude of mIPSC was not different between euploid and Ts65Dn mice or between Ts65Dn and Ts65Dn:Lhx6-Cre:DSCAMflox (Fig 2D and 2F). These results are consistent with the morphological results showing that the extra copy of DSCAM gene leads to an increase in the number of GABAergic boutons on PyN somas (Fig 1C–1F).
Basket and ChC cells constitute the parvalbumin-expressing (PV+) interneurons in neocortex [40]. Notably, normalizing DSCAM levels did not rescue the increased density of PV+ neurons in the ACC region of Ts65Dn mice (S5A and S5B Fig). Thus, the overexpressed DSCAM in the Ts65Dn neocortex causes excessive GABAergic synaptic transmission by increasing the number of GABAergic boutons and not by affecting the number of PV+ GABAergic neurons.
DSCAM overexpression increases ChC presynaptic terminals and boutons in Ts65Dn mice
Previous studies in Drosophila have demonstrated that Dscam levels determine the size of presynaptic terminals and that increased levels of Dscam lead to excessive growth of presynaptic terminals [3,49]. Whether an increase in DSCAM also causes overgrowth of presynaptic terminals in mice is unknown. Compared to basket cells [50], the morphology of neocortical ChCs is relatively stereotypical and reliably quantifiable [51–54]. Each ChC innervates roughly 200 PyNs at their axon initial segments (AISs) [55], where action potentials are generated [56,57].
We used the Nkx2.1-CreERT2 mouse line and the tdTomato reporter line Ai14 to label single ChCs in the neocortex [58] (Fig 3A). A single ChC extends only a few dendritic branches but several hundreds of presynaptic terminals, called axonal cartridges, each of which innervates an AIS of a PyNs [59]. The axonal cartridges and presynaptic boutons of single ChCs were quantified double-blindly at P28, a time after ChC development is complete [59]. The ChCs in layers II/III of the ACC were analyzed because the morphology of ChCs in this region is most stereotypical.
To determine whether the morphology of ChC axon terminals is altered in Ts65Dn neocortex and whether DSCAM triplication contributes to any morphological changes, we integrated Nkx2.1-CreERT2 and Ai14 in Ts65Dn and crossed female Ts65Dn mice with male DSCAM+/− mice. This genetic scheme yielded regular trisomic Ts65Dn mice (Ts65Dn:DSCAM+/+/+) as well as Ts65Dn that contained only 2 functional copies of DSCAM (Ts65Dn:DSCAM+/+/−) (Fig 3A).
Compared to euploid littermates, the total cartridge length, which is the sum of individual cartridges in the quantified volume, was increased by 42% (Fig 3B and 3C). In addition, ChCs in Ts65Dn mice showed a significant increase in both the number and size of synaptic boutons. The average bouton number per ChC was increased by 36% (Fig 3D and 3E), and the average size of presynaptic boutons was enlarged by 22% (Fig 3D and 3F). The average interbouton distance between neighboring boutons and the AIS length were not affected in the trisomy mice (S7A and S7B Fig). Thus, we found significantly increased presynaptic terminals and boutons in single ChCs in Ts65Dn mice.
Normalizing DSCAM levels rescued ChC presynaptic overgrowth in Ts65Dn mice. Compared with Ts65Dn littermates, the total cartridge lengths of single ChCs were reversed to levels indistinguishable from euploid in Ts65Dn:DSCAM+/+/− mice (Fig 3B and 3C). In addition, the increased bouton number and bouton size were rescued by normalizing DSCAM expression (Fig 3D–3F). No change was observed in the interbouton distance or the AIS length, as compared to either euploids or Ts65Dn mice (S7A and S7B Fig). These results demonstrate that ChC presynaptic terminal overgrowth in Ts65Dn mice is mainly caused by DSCAM overexpression.
Loss of DSCAM reduces the number of GABAergic boutons on PyN soma and axon initial segments
The studies presented above show that DSCAM overexpression in the trisomy mouse model leads to excessive GABAergic boutons on PyN somas and AIS. Does loss of DSCAM lead to the converse phenotypes? To answer this question, we evaluated perisomatic GABAergic boutons in the loss-of-function DSCAM mutant DSCAM2j. As reported previously [37,38], DSCAM protein was not detected in DSCAM2j/2j (DSCAM−/−) by western blotting (S8A Fig). Brain sections were triply stained with anti-Bassoon (for presynaptic active zone), anti-VGAT (for presynaptic GABAergic boutons), and anti-GRASP1 (for PyN soma and proximal dendrites). We quantified the data in a double-blinded fashion to avoid experimenter bias and compared the DSCAM−/−, DSCAM+/−, and DSCAM+/+ groups. The average number of GABAergic boutons around each PyN soma was reduced 41% in the neocortices of DSCAM−/− mice compared to DSCAM+/− mice (Fig 4A and 4B). The level of DSCAM protein in DSCAM+/− mice was 65% of that in DSCAM+/+ mice (S8B Fig). Consistent with the notion that DSCAM function in synaptic development is dose dependent [3], PyNs in DSCAM+/− mice also had fewer perisomatic GABAergic boutons than those in DSCAM+/+ mice (Fig 4C and 4D). These data suggest that DSCAM is required for forming the proper number of GABAergic boutons on PyN somas in the neocortex. Moreover, the dose dependence of DSCAM function highlights the importance of DSCAM expression levels in regulating synaptic development.
Similar to its role in presynaptic development in Drosophila [3,49], loss of DSCAM significantly impeded the development of ChC presynaptic terminals. Compared to heterozygous littermates, the average total cartridge length was reduced by 24% (Fig 5A and 5B). Moreover, the average numbers and sizes of presynaptic boutons were significantly reduced by 20% and 15%, respectively (Fig 5C–5E). No difference was observed in the interbouton distance or AIS length between these 2 groups (S7C and S7D Fig), indicating that DSCAM does not regulate bouton density. These results demonstrate that DSCAM is required for ChC presynaptic development in mice.
Consistent with the observation that normalizing DSCAM levels did not rescue the increased PV+ neuron density in Ts65Dn mice (S5A and S5B Fig), the number of PV+ neurons was unaffected by loss of DSCAM (S5C and S5D Fig).
Loss of DSCAM impairs GABAergic synaptic transmission to PyNs
To determine whether defective GABAergic bouton numbers caused by loss of DSCAM impairs GABAergic synaptic transmission, patch-clamp recordings in the whole-cell configuration were employed to record inhibitory currents in the PyNs in layers II/III of the ACC from acute neocortical brain slices. Consistent with impaired axonal growth and bouton number in ChCs, we found that the average frequency of mIPSCs was approximately 35% less in DSCAM−/− mice than that in heterozygous littermates (Fig 6A and 6B). In addition, the average amplitude of mIPSCs was reduced by 42%, suggesting that postsynaptic responses were impaired by loss of DSCAM (Fig 6C). Similar changes were observed in the frequency and amplitude of sIPSCs (Fig 6D–6F).
ChC axon terminal growth and bouton number are positively coupled to neocortical DSCAM levels
Presynaptic terminal growth and synaptogenesis are concurrent processes for forming proper neuronal connections [60]. Little is known about whether and how these 2 events are orchestrated in mammalian GABAergic interneurons. The sparse labeling of ChCs offers an opportunity to address these questions at single-cell resolution. We examined the relationship between cartridge length and 3 morphological aspects of synaptic boutons, namely bouton number, size, and density (as reflected by the interbouton distance), in single ChCs. We found a strong correlation between the cartridge length and the bouton number of each ChC in both wild-type (euploid) (R2 = 0.82, p < 10−7) and Ts65Dn mice (R2 = 0.79, p < 10−15) (S9A Fig). Although DSCAM positively regulated both cartridge length and bouton number (Figs 3B–3F and 5), loss of DSCAM did not impair their coupling (R2 = 0.89, p < 10−8) (S9B Fig). There was also a significant correlation between cartridge length and bouton size in both wild-type and Ts65Dn mice (S9C Fig), though it was weaker than that between cartridge length and bouton number. Loss of DSCAM seemed to mildly impair the coupling between cartridge length and bouton size (S9D Fig). There was no correlation between cartridge length and bouton density in any of the genotypes tested (S9E and S9F Fig). Taken together, these results suggest that presynaptic terminal growth and bouton number are positively coupled in ChC development.
In Drosophila, Dscam levels determine the size of presynaptic arbors [3]. Western blotting results suggested that DSCAM levels in the neocortex exhibited individual variations in euploid, Ts65Dn, and Ts65Dn:DSCAM+/+/− mice (S10A Fig). We plotted the neocortical DSCAM level of each mouse, as assayed by western blotting, against the average cartridge length, bouton number, size, or density in each mouse. We observed a strong correlation between DSCAM levels and cartridge lengths, bouton number, and bouton sizes in mice (S10B–S10D Fig). In contrast, no correlation was found between DSCAM levels and interbouton distance (S10E Fig), again supporting that bouton density is not regulated by DSCAM (S7 Fig). The dose dependence highlights the importance of DSCAM expression levels in regulating ChC presynaptic development.
Discussion
In this study, we show that the extra copy of DSCAM in a mouse model of DS leads to presynaptic overgrowth in ChCs and basket cells, 2 major types of inhibitory neurons in the neocortex. The hyper-innervation and excessive GABAergic inhibition of PyNs in Ts65Dn were rescued by normalizing the DSCAM levels. The converse phenotypes were observed in DSCAM loss-of-function mutant mice. The sensitivity of GABAergic synapse development and function to DSCAM expression levels suggest that dysregulated DSCAM expression may underlie GABAergic dysfunction in neurological disorders that exhibit abnormal DSCAM expression, including DS, ASDs, intractable epilepsy, bipolar disorders, and, possibly, Fragile X syndrome.
The effects of DSCAM are unlikely to stem from mitotic proliferation for several reasons. First, DSCAM is expressed in differentiating neurons but not mitotic progenitors [1,61–63]. Second, our results show that normalizing DSCAM levels does not rescue the increased density of PV+ neurons in the ACC region of Ts65Dn mice (S5A and S5B Fig). Consistently, the number of cortical PV+ neurons was not affected in DSCAM null mice (S5C and S5D Fig).
DSCAM expression levels determine presynaptic terminal sizes in mammalian neurons
The stereotypical morphology of ChCs axon arbors and presynaptic terminals are advantageous for quantitative assessment [51,52]. Moreover, recent advances in genetic labeling of ChCs have allowed sparse labeling of single ChCs for quantifying presynaptic terminals at single-cell resolution [58,64]. By taking advantage of this system, we show in this study that DSCAM overexpression causes presynaptic overgrowth of ChCs in the neocortex. Notably, ChC cartridge length, bouton number, and bouton sizes correlate with DSCAM expression levels (S10B–S10D Fig), suggesting the sensitivity of ChC development to DSCAM levels. Thus, this work supports a conserved role of DSCAM in regulating presynaptic terminal growth in Drosophila and mice.
Whether DSCAM functions cell-autonomously to promote ChC presynaptic terminal growth remains an open question due to technical difficulties. Genetic deletion of DSCAM in single ChCs is challenging because the Cre activity in Nkx2.1-CreER mouse line is weak. Since administration of tamoxifen cannot guarantee the deletion of target genes in all or vast majority of cells in floxed mice, immunostaining or in situ hybridization is required to confirm the deletion. However, available anti-DSCAM antibodies are not conducive for immunostaining in the neocortex [6]. Moreover, the experimental procedures for in situ hybridization are not compatible with morphological studies of ChCs by immunostaining. Future studies with reliable ChC-specific genetic deletions (e.g., via a stronger Cre) will determine whether DSCAM functions cell-autonomously.
Our studies using an Lhx6-Cre mouse line that targets GABAergic interneurons show that the extra copy of DSCAM in GABAergic neurons leads to the excessive GABAergic boutons on PyN somas (Fig 1D and 1F) and increased mIPSC frequencies in PyNs (Fig 2D–2F). The Lhx6-Cre transgene is not only expressed in basket cells, which forms the perisomatic GABAergic synapses on PyNs [40,41], but also expressed in ChC cells and somatostatin+ GABAergic neurons [46,47]. As such, these results do not demonstrate that the extra copy of DSCAM in basket cells causes the excessive boutons or increased mIPSC frequencies. Testing the cell-autonomous functions of DSCAM in perisomatic synapse development requires removing the extra copy of DSCAM specifically in basket cells.
The role of DSCAM in GABAergic synaptic transmission in the neocortex
Whole-cell patch-clamp recordings showed that mIPSC frequency of PyNs was increased in Ts65Dn mice and that normalizing DSCAM levels rescued this change (Fig 2). Moreover, mIPSC frequency of PyNs was reduced in DSCAM−/− mice (Fig 6A and 6B). Because mIPSC frequency indicates input numbers and presynaptic release sites, these findings are consistent with a role of DSCAM in increasing bouton numbers in basket cells (Figs 1C, 1E, and 4).
We found no difference in mIPSC amplitude of PyNs between euploid and Ts65Dn mice (Fig 2A and 2C), suggesting that postsynaptic responses may not be affected by the trisomy. By contrast, mIPSC amplitude of PyNs was reduced in DSCAM−/− mice (Fig 6C), suggesting that postsynaptic responses were impaired by loss of DSCAM. Taken together, these results indicate that while DSCAM might be essential for postsynaptic responses at the inhibitory synapses formed on PyNs, their overexpression is insufficient to change the postsynaptic responses, at least in Ts65Dn mice.
A potential role of DSCAM in excitatory synaptic transmission in the neocortex in DS mouse model
In this study, we found that the sEPSC frequency was also increased in PyNs in the ACC, which was reduced by normalizing DSCAM gene dosage (S4I Fig). This result suggests that the activity of excitatory presynaptic terminals is also regulated by DSCAM expression levels. By contrast, we did not observe any difference in the frequency of sEPSCs in ChCs (S11 Fig), suggesting that HSA21 trisomy has cell type–specific effects on excitatory synaptic transmission in the neocortex. A complete analysis of DSCAM’s contribution to the excitatory synaptic transmission in DS models is an interesting future direction.
Similar to PyNs, ChCs did not exhibit any difference in either their single action potential or membrane properties among euploid, Ts65Dn, and Ts65Dn:DSCAM+/+/− mice (S11A–S11F Fig), except for a minor change in the threshold in Ts65Dn mice (S11B Fig). This minor change has no impact on neuronal excitability since rheobase was not affected (rheobase is defined as the minimal current required to evoke an action potential) (S11H Fig). Different from PyNs, both ChCs in Ts65Dn mice and those in Ts65Dn:DSCAM+/+/− mice exhibited lower firing frequencies than in euploid mice (S11G Fig). This suggests that ChCs might receive increased inhibitory inputs or reduced excitatory inputs, independent of DSCAM. The fact that PyN firing rates are indistinguishable in euploid, Ts65Dn, and Ts65Dn:DSCAM+/+/− mice (S4G Fig) suggests the excessive GABAergic inhibition on PyNs might be balanced by excessive glutamatergic excitation.
The coupling between presynaptic terminal growth and bouton number in ChCs
Among the different types of GABAergic neurons, ChCs are thought to be a powerful source of inhibition in the neocortex [65]. These neurons form unique axo-axonic GABAergic synapses that selectively innervate PyNs at their AIS, where action potentials are generated [56,57]; each ChC innervates roughly 200 PyNs [55]. Impaired ChC presynaptic growth is present in individuals with epilepsy and schizophrenia, both of which are thought to be caused, in part, by disrupted GABAergic signaling [65–69]. Recent studies demonstrate that deleting Erbb4, a schizophrenia-associated gene, in ChCs causes a schizophrenia-like phenotype in mice, indicating a causal relationship between ChC defects and schizophrenia [46,54]. In addition to ErbB4, Neuregulin 1, DOCK7, Fgf13, and L1CAM have also been found to regulate synapse formation between ChCs and PyNs [51–53,70].
In the present study, detailed investigation of the cartridge growth and bouton numbers at single-cell resolution uncovered several interesting features of ChC development. First, presynaptic cartridge growth is strongly associated with bouton number and, to a lesser extent, bouton size (S9A–S9D Fig). This observation supports the synaptotropic model proposing that synaptogenesis stabilizes axonal arbor growth in neurodevelopment [71]. Second, the factors that regulate cartridge growth and synaptogenesis are not necessarily the factors coupling these 2 processes. Although DSCAM regulates both cartridge growth and bouton number, the coupling of these 2 processes remains intact in mice that are deficient of DSCAM function, suggesting that DSCAM is not the coupling factor. Identifying and distinguishing coupling factors from regulators is an important step toward a mechanistic understanding of ChC development.
Possible mechanisms by which DSCAM regulates inhibitory synapses
By restoring DSCAM level in trisomy background, we demonstrate the causality of DSCAM’s role in inhibitory synaptic changes in a DS mouse model. The detailed molecular mechanism related to DSCAM’s role remains elusive. Conditional knockout of 1 copy of the DSCAM gene in GABAergic neurons in the trisomy background reduced the number of GABAergic boutons and mIPSC frequency to the normal level (Figs 1D, 1F, 2D–2F, and S3D–S3F), suggesting that increased level of DSCAM in GABAergic neurons is responsible for the synaptic changes. Moreover, we did not observe changes in the size of PyNs or the length of AIS (S1D, S7B, and S7D Figs), further supporting that DSCAM’s role in inhibitory synapses is caused by their expression in GABAergic neurons. Previous studies have shown several molecules that mediate signaling downstream of DSCAM, including Abelson tyrosine kinase [49], Pak1 [72–74], and Dock [74]. Moreover, DSCAM might regulate electric activity of GABAergic neurons and consequently changes their presynaptic terminals and synapses. These are interesting possible mechanisms to investigate in the future.
Insights into other brain disorders
Altered DSCAM expression levels have been associated with several brain disorders, including DS, ASD, intractable epilepsy and bipolar disorder [6–11], and, possibly, Fragile X syndrome [3,4,12,13]. The present work has established a causal relationship between dysregulated DSCAM levels and the developmental and functional defects of GABAergic neurons. The dose-dependent function of DSCAM suggests that dysregulated DSCAM levels may be a common pathogenic driver of GABAergic dysfunctions related to neurological diseases. For example, genetic analyses have revealed multiple disruptive single-nucleotide variants (SNVs) and copy number variants (CNVs) in the DSCAM gene in idiopathic ASD individuals, raising the possibility of altered DSCAM expression levels [7–9,75]. Given the regulation of GABAergic signaling by DSCAM levels discovered in the present study and the established role of impaired GABAergic signaling in ASD [76], one may hypothesize that reduced DSCAM expression causes impaired GABAergic signaling in ASD. In support of this idea, some ASD individuals with CNV of deleted enhancer region in DSCAM show nonfebrile seizures [9], a symptom also found in mice with deficient DSCAM function [77]. It is thus important to examine DSCAM levels in postmortem samples of autistic individuals and determine whether altered DSCAM expression causes GABAergic dysfunctions in ASD mouse models.
Methods and materials
Ethics statement
The Institutional Animal Care and Use Committees at University of Michigan reviewed and approved all experimental procedures involving mice (protocol numbers PRO00005862 and PRO00007778). For immunohistochemistry, mice were killed by CO2, immediately followed by intracardial infusion (see below). For electrophysiology, mice were decapitated under isoflurane and USP anesthesia, and the brains were quickly removed from the skull for further processing (see below).
Mouse breeding and tamoxifen administration
Age-matched littermates were used for all experiments. The Ts65Dn mouse line (Ts(17(16))65Dn) was purchased from Jackson Laboratory (Stock No: 005252) and maintained by crossing with C57BL/C3H F1 hybrid males created from breeding C57BL/6J (Stock No: 000664) with the C3Sn.BLiA-Pde6b+/DnJ line (Stock No: 003648).
For studying the perisomatic GABAergic boutons formed on PyNs, female Ts65Dn mice (Ts(17(16))65Dn) on a C57BL/C3H mixed background were bred to male C3H/HeDiSn-Dscam2j/GrsrJ mice from Jackson Laboratory (Stock No: 006038) to generate euploid, Ts65Dn, and Ts65Dn:DSCAM+/+/− littermates for data collection.
To determine whether the extra copy of DSCAM gene within GABAergic neurons leads to the excessive GABAergic boutons on PyN somas, we normalized DSCAM gene dosage within cortical GABAergic neurons. Lhx6-Cre mice were crossed with DSCAMflox mice (Stock No: 17689) to generate male Lhx6-Cre+/−, DSCAMflox +/− (Lhx6-Cre/DSCAMflox) mice, which, in turn, were bred to female Ts65Dn (Ts(17(16))65Dn; on a C57BL/C3H mixed background) to generate (1) Lhx6-Cre+/−:euploid; (2) Ts65Dn:Lhx6-Cre+/−; and (3) Ts65Dn:Lhx6-Cre+/−/DSCAMflox littermates. Tamoxifen (Sigma, T5648-1G), dissolved in corn oil, was delivered to pregnant mothers at E18 by intraperitoneal injection at the dosage of 80 mg/kg body weight to normalize DSCAM gene dosage within cortical GABAergic neurons.
For labeling single ChCs in Ts65Dn mice, Ts65Dn females were crossed with Nkx2.1-CreER+/−, Ai14−/−, DSCAM+/− male mice of mixed C57BL/C3H background to obtain euploid, Ts65Dn, and Ts65Dn:DSCAM+/+/− littermates with Nkx2.1-CreER+/−, Ai14+/− transgenes. Tamoxifen (Sigma, T5648-1G), dissolved in corn oil, was delivered to P0 pups by intraperitoneal injection at the dosage of 80 mg/kg body weight. Pseudodams were prepared in advance to lactate the pups as the pups were often discarded by Ts65Dn dams after tamoxifen administration. For labeling single ChCs in DSCAM2j mice, female DSCAM+/− mice of C3H background were crossed with Nkx2.1-CreER+/−, Ai14−/−, DSCAM+/− male mice of mixed C57BL/C3H background to obtain DSCAM+/− and DSCAM−/− pups with Nkx2.1-CreER+/−, Ai14+/− transgenes. Tamoxifen was delivered to P0 pups as described above. Strong pups were killed at P0 to keep the litter size 4 to 5 to increase the surviving rate of DSCAM−/− pups. Nkx2.1-CreER+/−, Ai14−/−, DSCAM+/− male mice were removed from the cage before female laboring as the male adults is likely to attack and kill DSCAM−/− pups.
Because DSCAM−/− pups are weak, in the study of perisomatic GABAergic boutons, we killed the wild-type littermates at P5 to P7 to promote the survival of DSCAM−/− pups. It was thus almost impossible to collect wild-type, heterozygotes, and homozygotes from the same litter. Therefore, we compared perisomatic GABAergic boutons between DSCAM+/+ and DSCAM+/− mice and between DSCAM+/− and DSCAM−/− mice (Fig 4).
For electrophysiology recordings, Ts65Dn females were crossed with C3H DSCAM+/− male mice to obtain euploid, Ts65Dn, and Ts65Dn: DSCAM+/+/− littermates. C3H DSCAM+/− mice were interbred to obtain DSCAM+/− and DSCAM−/− pups for recordings.
PCR genotyping was performed on purified tail tips at least 2 times to confirm the genotype according to the protocol by Jackson Laboratory. All work involving mice was approved by the University of Michigan Institutional Animal Care and Use Committee (IACUC) and in accordance with the National Research Council Guide for the Care and Use of Laboratory Animals (NIH).
Immunohistochemistry
P28 mice were killed by CO2 and immediately followed by intracardial infusion of 4% paraformaldehyde (PFA) with 4% sucrose in 1× PBS. The brains were then removed and postfixed in 4% PFA overnight at 4°C, followed by incubation in 30% sucrose (wt/vol) for at least 1 day. The brains were embedded in the OCT compound (Fisher HealthCare), frozen in −20°C overnight, and then sectioned to 100 μm-thick slices with a Leica CM3050S cryostat. Sectioned brain slices were kept in 1× PBS containing 0.05% sodium azide at 4°C until immunostaining.
For ChC and AIS staining, coronal brain sections (100 μm) were blocked with 8% BSA in PBST (1× PBS + 0.1% Triton x-100) containing 0.05% sodium azide at 37°C for 1 hour and then incubated with the following primary antibodies in the blocking solution at 37°C overnight. The AIS was immunolabeled using an anti-phospho-IκB antibody (pIκB) [51,52,58,78], which strongly correlates with the AIS labeled by ankyrin-G antibodies in the mouse neocortex [79] (S6B and S6C Fig). Primary antibodies used were anti-mCherry (SICGEN, AB0081; 1:300) for neuronal morphology and anti-phospho-Iκβ-α (Cell Signaling, 14D4 rabbit monoclonal antibody; 1:500) for labeling the AIS. After washing 3 times (1 hour each time) at 37°C in PBST, brain slices were incubated with the following secondary antibodies in the blocking solution at 37°C overnight: donkey anti-goat-rhodamine RX (RRX) (Jackson ImmunoResearch, 705-297-003; 1:300), donkey anti-rabbit-Alexa Fluor 488 (Jackson ImmunoResearch, 711-545-152; 1:300). After washing 3× for a total of 1 hour at 37°C in PBST, the slices were mounted in sRIMS [80].
The procedure for staining of GABAergic neurons and PyNs was the same as above, except that antibody incubations were done at room temperature (RT) and different primary antibodies were used. Primary antibodies used were anti-parvalbumin (Swant, PVG213; 1:1,000), anti-CAMKIIα (LSBio, 6G9; 1:5,000). Secondary antibodies used were donkey anti-goat-RRX (Jackson ImmunoResearch, 705-297-003; 1:500) and donkey anti-mouse-Alexa Fluor 488 (Jackson ImmunoResearch, 715-545-150; 1:500).
For staining perisomatic GABAergic boutons, antigen retrieval was conducted in 10 μM sodium citrate for 20 minutes at 95°C [81]. After a brief rinse in PBS, the slices were blocked in blocking buffer (1× PBS, 0.3% Triton x-100, 3% normal donkey serum, 0.05% sodium azide) for 1 hour at RT and then incubated with the following primary antibodies in the blocking solution at 4°C overnight: mouse anti-Bassoon (ENZO, SAP7F407; 1:1,000), guinea pig anti-VGAT (Synaptic System, 131 004; 1:1,000), rabbit anti-GRASP1 (1:2,000) [45]. After washing 3 times (20 minutes each time) at RT in PBST, brain slices were incubated with the following secondary antibodies in the blocking solution at RT 3 hours: donkey anti-mouse-Alexa Fluor 488 (Jackson ImmunoResearch, 715-545-150; 1:300), donkey anti-guinea-pig-RRX (Jackson ImmunoResearch, 706-295-148; 1:300), donkey anti-rabbit-Alexa Fluor 647 (Jackson ImmunoResearch, 711-605-152; 1:300). The slices were mounted for imaging after washing 3 times for a total of 1 hour at RT in PBST.
Image acquisition and quantitative analysis
All images were acquired from cortical layer II/III by using a Leica SP5 confocal microscope equipped with a resonant scanner, except the samples for perisomatic GABAergic boutons (see below). For ChCs imaging, different fluorescence channels were imaged sequentially with the pinhole set at airy 1. A 63× objective lens with a numerical aperture of 1.4 was used. Confocal image stacks were collected with 100 continuous optical sections at 0.3-μm z-steps. The cell body was positioned around the middle of the 30-μm in depth. The axonal cartridges and presynaptic boutons of single ChCs were quantified in a three-dimensional volume defined based on the position of the ChC soma (S6A Fig). Before quantification, the image stacks were maximally projected along the z-axis. A region of 120 μm (length) × 80 μm (width) with the cell body in the top middle was set for quantification. Cartridges and boutons that colocalized with AIS were quantified by the NeuroLucida software (MBF Bioscience). Cartridge/bouton number was defined as the number of cartridges/boutons within this region. AIS-colocalized cartridges and presynaptic boutons were quantified. Cartridge length was defined as the distance from the first bouton that colocalized with AIS to the last one colocalized with AIS in that cartridge. Bouton size was defined as the length of the bouton in parallel to the AIS. We quantified the sizes of boutons in the 10 cartridges nearest to the cell body. Interbouton distance was defined as the distance between 2 neighboring boutons.
Samples for perisomatic GABAergic boutons were imaged on a Leica SP8 confocal microscope with a 63× objective lens (NA 1.4). For each PyN, a single confocal image was taken at the z-position where PyN cell body occupied the most area. Images were deconvoluted with the Huygens software (Scientific Volume Imaging). Perisomatic VGAT+ and Bassoon+ puncta were quantified in defined PyN soma regions, as shown in S1C Fig, by the NeuroLucida software (MBF Bioscience). Perisomatic GABAergic boutons were counted as puncta that contained pixels positive for both VGAT and Bassoon.
To eliminate experimenter bias, these experiments were carried out in double-blind fashion. Two double-blind methods were used. First, the images acquired by the primary experimenter was coded and randomized by the second lab member. After the primary experimenter quantified the data, the data were decoded for statistical analysis. Second, the mouse brains from the primary experimenter were coded and randomized by the second lab member. The second lab member sent the coded mouse brains to the third lab member for sectioning. After the primary experimenter immunostained and quantified the encoded brain sections, the data were decoded for a final statistical analysis.
Western blotting
Mouse neocortices were removed immediately after PFA perfusion. Similar volumes of tissues were homogenized in SDS sample buffer and loaded for electrophoresis. The proteins were transferred to PVDF membranes and blocked with 5% milk (wt/vol) for 1 hour at RT. The blots were incubated overnight at 4°C with goat anti-DSCAM (R&D Systems, AF3666; 1:500), anti-APP (Cell Signaling Technology, 2452; 1:1,000), or mouse anti-tubulin (12G10, 1:5,000, DSHB). After washing, blots were incubated for 2 hours with HRP-conjugated secondary antibodies (1:5,000) and developed by chemiluminescence (Pierce, 32106). Quantification was performed using ImageJ.
Electrophysiology recordings and analysis
Electrophysiological recordings of single action potential properties, firing frequency, and spontaneous and miniature postsynaptic currents were performed as described previously [81]. Brains were obtained from euploid, Ts65Dn, and Ts65Dn/DSCAM+/+/− mice at around P28. The animals were killed by decapitation under isoflurane and USP anesthesia. The brain was quickly removed from the skull and placed in 4°C slicing solution containing (in mM) 62.5 NaCl, 2.5 KCl, 1.25 KH2PO4, 26 NaHCO3, 5 MgCl2, 0.5 CaCl2, 20 glucose, and 100 sucrose (pH maintained at 7.4 by saturation with 95% O2 + 5% CO2). Acute coronal brain slices (300 to 350 μm thick) containing layers II/III of the ACC neocortex were cut with a microtome (VF-300, Compresstome). The slices were then transferred to a holding chamber and maintained at RT in artificial cerebrospinal fluid (ACSF) containing (in mM) 125 NaCl, 2.9 KCl, 1.25 KH2PO4, 26 NaHCO3, 1 MgCl2, 2 CaCl2, and 20 glucose (pH 7.4) (with 95% O2 and 5% CO2 bubbling through the solution) for at least 1 hour prior to recording. After equilibration, individual slices were transferred to the recording chamber continuously perfused with ACSF (1 to 2 mL/minute). Recording micropipettes were pulled from borosilicate glass capillaries (1.5 mm O.D. Harvard Apparatus) for a final resistance of 3 to 6 MΩ and filled with a solution containing 135 CsCl, 4 NaCl, 0.4 GTP, 2 Mg-ATP, 0.5 CaCl2, 5 EGTA, and 10 HEPES. The signals were recorded with an Axoclamp 700B amplifier (Axon Instruments, Union City, CA). Current and voltage clamp recordings were obtained from PyNs and ChCs in layers II/III of the ACC region. The cells in these brain regions were identified using a Nikon Eclipse FN-1 microscope with a 40× water-immersion objective and a DAGE MTI IR-1000 video camera. Neurons were visualized using IR-DIC to evaluate their orientation and morphology. ChC interneurons were identified by the red fluorescence from Nkx2.1-CreERT2/Ai14. Whole-cell patch-clamp recordings were performed with a high cell resistance (greater than 8 GΩ before break-in). sIPSC and mIPSC recordings in voltage-clamp configuration were acquired at 2 kHz fixing the voltage at −70 mV. The IPSCs were recorded in the presence of the NMDA receptor antagonist DL-2-amino-5-phosphonopentanoic acid (AP-5) at 50 mM and the AMPA/kainite antagonist 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) at 10 μM. For measurement of mIPSCs, 1 μM tetrodotoxin (TTX) was added to the perfusion solution to block synaptic responses dependent on the AP.
For studying the excitability and EPSCs, the CsCl in the internal solution was replaced by K-gluconate, and the signals were recorded with a low-pass filter at 10 kHz. Whole-cell patch-clamp recordings in current clamp configuration with a high cell resistance were obtained for PyNs and ChCs [81]. The neurons were characterized electrophysiologically by applying negative and positive current pulses of 10 pA and 1000 ms to calculate the firing frequency and positive pulses of 50 ms to measure the features for the single AP. EPSCs were measured in the presence of bicuculline (10 μM) while holding the resting membrane potential at −70 mV using K-gluconate internal solution. Access resistance was monitored throughout the experiment, and results were discarded if changes greater than 20% occurred. Peak events were identified automatically using Minianalysis (Synaptosoft) and visually monitored to exclude erroneous noise. The frequency, amplitude, and distribution of events were analyzed. One euploid neuron (1 out of 20) with mIPSC frequency 8.9 Hz was defined as an outlier by the Grubbs test and removed from quantification. Mean values were compared using the Student t test. To analyze evoked action potential frequency from neurons in acute brain slices, two-way ANOVA and Tukey’s post hoc analysis were performed. Data are presented as mean ± SEM.
Statistical analysis
Data are presented as mean ± SEM. Unless specified otherwise, comparisons of mean differences between groups were performed by one-way ANOVA for multigroup comparisons and post hoc Student t tests for pair-wise comparisons. P < 0.05 was considered to be statistically significant. For all quantification, *: p < 0.05; **: p < 0.01; ***: p < 0.001; ****: p < 0.0001; ns: not significant (p > 0.05).
Supporting information
Acknowledgments
We thank Drs. Seth Blackshaw and Thomas Kim for the Lhx6-Cre mice. We also thank Drs. Roman Giger, Jun Wu, Andrew Nelson, Dawen Cai, Jonathan Flak, and Martin Myers for sharing reagents or technical support, Miao He, Yongjie Hou, Pedro Lowenstein, Ken Inoki, Yukiko Yamashita, and Dawen Cai for helpful discussions.
Abbreviations
- ACC
anterior cingulate cortex
- ACSF
artificial cerebrospinal fluid
- AIS
axon initial segment
- APP
amyloid precursor protein
- ASD
autism spectrum disorder
- ChC
chandelier cell
- CNV
copy number variant
- DS
Down syndrome
- DSCAM
Down syndrome cell adhesion molecule
- HSA21
human chromosome 21
- mIPSC
miniature inhibitory postsynaptic current
- PFA
paraformaldehyde
- PyN
pyramidal neuron
- P28
postnatal day 28
- RT
room temperature
- sIPSC
spontaneous inhibitory postsynaptic current
- SNV
single-nucleotide variant
Data Availability
The data that underlie the figures are publicly accessible in https://doi.org/10.5281/zenodo.7714234.
Funding Statement
This work was supported by grants from the National Institutes of Health (R21NS094091, R01MH112669, and R01EB028159 to B.Y.; R37NS076752 to LLI), a seed grant from Brain Research Foundation to B.Y., a grant from the Protein Folding Disease Initiative of the University of Michigan to B.Y., startup funds from the University of Michigan Department of Pharmacology to P.M.J., and a University of Michigan Rackham Merit Fellowship and a MI-BRAIN Predoctoral Fellowship to J.M.H.. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
References
- 1.Yamakawa K, Huo YK, Haendel MA, Hubert R, Chen XN, Lyons GE, et al. DSCAM: a novel member of the immunoglobulin superfamily maps in a Down syndrome region and is involved in the development of the nervous system. Hum Mol Genet. 1998;7(2):227–237. doi: 10.1093/hmg/7.2.227 WOS:000071771900010 . [DOI] [PubMed] [Google Scholar]
- 2.Schmucker D, Chen B. Dscam and DSCAM: complex genes in simple animals, complex animals yet simple genes. Genes Dev. 2009;23(2):147–156. doi: 10.1101/gad.1752909 . [DOI] [PubMed] [Google Scholar]
- 3.Kim JH, Wang X, Coolon R, Ye B. Dscam expression levels determine presynaptic arbor sizes in Drosophila sensory neurons. Neuron. 2013;78(5):827–838. doi: 10.1016/j.neuron.2013.05.020 ; PubMed Central PMCID: PMC3709448. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Cvetkovska V, Hibbert AD, Emran F, Chen BE. Overexpression of Down syndrome cell adhesion molecule impairs precise synaptic targeting. Nat Neurosci. 2013;16(6):677–682. doi: 10.1038/nn.3396 . [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Lowe SA, Hodge JJL, Usowicz MM. A third copy of the Down syndrome cell adhesion molecule (Dscam) causes synaptic and locomotor dysfunction in Drosophila. Neurobiol Dis. 2018;110:93–101. Epub 2017/12/03. doi: 10.1016/j.nbd.2017.11.013 ; PubMed Central PMCID: PMC5773243. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Saito Y, Oka A, Mizuguchi M, Motonaga K, Mori Y, Becker LE, et al. The developmental and aging changes of Down’s syndrome cell adhesion molecule expression in normal and Down’s syndrome brains. Acta Neuropathol. 2000;100(6):654–664. Epub 2000/11/15. doi: 10.1007/s004010000230 . [DOI] [PubMed] [Google Scholar]
- 7.O’Roak BJ, Stessman HA, Boyle EA, Witherspoon KT, Martin B, Lee C, et al. Recurrent de novo mutations implicate novel genes underlying simplex autism risk. Nat Commun. 2014;5:5595. Epub 2014/11/25. doi: 10.1038/ncomms6595 ; PubMed Central PMCID: PMC4249945. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Krumm N, Turner TN, Baker C, Vives L, Mohajeri K, Witherspoon K, et al. Excess of rare, inherited truncating mutations in autism. Nat Genet. 2015;47(6):582–588. Epub 2015/05/12. doi: 10.1038/ng.3303 ; PubMed Central PMCID: PMC4449286. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Turner TN, Hormozdiari F, Duyzend MH, McClymont SA, Hook PW, Iossifov I, et al. Genome Sequencing of Autism-Affected Families Reveals Disruption of Putative Noncoding Regulatory DNA. Am J Hum Genet. 2016;98(1):58–74. Epub 2016/01/11. doi: 10.1016/j.ajhg.2015.11.023 ; PubMed Central PMCID: PMC4716689. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Shen L, Xiao Z, Pan YM, Fang M, Li CS, Chen D, et al. Altered Expression of Dscam in Temporal Lobe Tissue From Human and Experimental Animals. Synapse. 2011;65(10):975–982. doi: 10.1002/syn.20924 WOS:000294555400001 . [DOI] [PubMed] [Google Scholar]
- 11.Amano K, Yamada K, Iwayama Y, Detera-Wadleigh SD, Hattori E, Toyota T, et al. Association study between the Down syndrome cell adhesion molecule (DSCAM) gene and bipolar disorder. Psychiatr Genet. 2008;18(1):1–10. WOS:000252723700001. doi: 10.1097/YPG.0b013e3281ac238e . [DOI] [PubMed] [Google Scholar]
- 12.Brown V, Jin P, Ceman S, Darnell JC, O’Donnell WT, Tenenbaum SA, et al. Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell. 2001;107(4):477–487. Epub 2001/11/24. doi: 10.1016/s0092-8674(01)00568-2 . [DOI] [PubMed] [Google Scholar]
- 13.Darnell JC, Van Driesche SJ, Zhang C, Hung KY, Mele A, Fraser CE, et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell. 2011;146(2):247–261. Epub 2011/07/26. doi: 10.1016/j.cell.2011.06.013 ; PubMed Central PMCID: PMC3232425. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Santos RA, Fuertes AJC, Short G, Donohue KC, Shao H, Quintanilla J, et al. DSCAM differentially modulates pre- and postsynaptic structural and functional central connectivity during visual system wiring. Neural Dev. 2018;13(1):22. doi: 10.1186/s13064-018-0118-5 ; PubMed Central PMCID: PMC6138929. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Bruce FM, Brown S, Smith JN, Fuerst PG, Erskine L. DSCAM promotes axon fasciculation and growth in the developing optic pathway. Proc Natl Acad Sci U S A. 2017;114(7):1702–1707. doi: 10.1073/pnas.1618606114 . [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Fernandez F, Morishita W, Zuniga E, Nguyen J, Blank M, Malenka RC, et al. Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat Neurosci. 2007;10(4):411–413. doi: 10.1038/nn1860 . [DOI] [PubMed] [Google Scholar]
- 17.Colas D, Chuluun B, Warrier D, Blank M, Wetmore DZ, Buckmaster P, et al. Short-term treatment with the GABAA receptor antagonist pentylenetetrazole produces a sustained pro-cognitive benefit in a mouse model of Down’s syndrome. Brit J Pharmacol. 2013;169(5):963–973. doi: 10.1111/bph.12169 WOS:000320270200002 . [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Braudeau J, Dauphinot L, Duchon A, Loistron A, Dodd RH, Herault Y, et al. Chronic Treatment with a Promnesiant GABA-A alpha5-Selective Inverse Agonist Increases Immediate Early Genes Expression during Memory Processing in Mice and Rectifies Their Expression Levels in a Down Syndrome Mouse Model. Adv Pharm Sci. 2011;2011:153218. Epub 2011/10/27. doi: 10.1155/2011/153218 ; PubMed Central PMCID: PMC3199058. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Braudeau J, Delatour B, Duchon A, Pereira PL, Dauphinot L, de Chaumont F, et al. Specific targeting of the GABA-A receptor alpha5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice. J Psychopharmacol. 2011;25(8):1030–1042. Epub 2011/06/23. doi: 10.1177/0269881111405366 ; PubMed Central PMCID: PMC3160204. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Martinez-Cue C, Martinez P, Rueda N, Vidal R, Garcia S, Vidal V, et al. Reducing GABAA alpha5 receptor-mediated inhibition rescues functional and neuromorphological deficits in a mouse model of down syndrome. J Neurosci. 2013;33(9):3953–3966. Epub 2013/03/01. doi: 10.1523/jneurosci.1203-12.2013 . [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Reeves RH, Irving NG, Moran TH, Wohn A, Kitt C, Sisodia SS, et al. A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat Genet. 1995;11(2):177–184. doi: 10.1038/ng1095-177 . [DOI] [PubMed] [Google Scholar]
- 22.Rueda N, Florez J, Martinez-Cue C. Mouse Models of Down Syndrome as a Tool to Unravel the Causes of Mental Disabilities. Neural Plast. 2012. doi: 10.1155/2012/584071 WOS:000305060100001 . [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Fernandez F, Garner CC. Episodic-like memory in Ts65Dn, a mouse model of Down syndrome. Behav Brain Res. 2008;188(1):233–237. doi: 10.1016/j.bbr.2007.09.015 ; PubMed Central PMCID: PMC3230531. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Kleschevnikov AM, Belichenko PV, Faizi M, Jacobs LF, Htun K, Shamloo M, et al. Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists. J Neurosci. 2012;32(27):9217–9227. doi: 10.1523/JNEUROSCI.1673-12.2012 ; PubMed Central PMCID: PMC3411326. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Kleschevnikov AM, Belichenko PV, Gall J, George L, Nosheny R, Maloney MT, et al. Increased efficiency of the GABAA and GABAB receptor-mediated neurotransmission in the Ts65Dn mouse model of Down syndrome. Neurobiol Dis. 2012;45(2):683–691. doi: 10.1016/j.nbd.2011.10.009 ; PubMed Central PMCID: PMC3259223. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Kleschevnikov AM, Belichenko PV, Villar AJ, Epstein CJ, Malenka RC, Mobley WC. Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. J Neurosci. 2004;24(37):8153–8160. doi: 10.1523/JNEUROSCI.1766-04.2004 . [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Costa AC, Grybko MJ. Deficits in hippocampal CA1 LTP induced by TBS but not HFS in the Ts65Dn mouse: a model of Down syndrome. Neurosci Lett. 2005;382(3):317–322. doi: 10.1016/j.neulet.2005.03.031 . [DOI] [PubMed] [Google Scholar]
- 28.Siarey RJ, Stoll J, Rapoport SI, Galdzicki Z. Altered long-term potentiation in the young and old Ts65Dn mouse, a model for Down Syndrome. Neuropharmacology. 1997;36(11–12):1549–1554. doi: 10.1016/s0028-3908(97)00157-3 . [DOI] [PubMed] [Google Scholar]
- 29.Contestabile A, Magara S, Cancedda L. The GABAergic Hypothesis for Cognitive Disabilities in Down Syndrome. Front Cell Neurosci. 2017;11:54. doi: 10.3389/fncel.2017.00054 ; PubMed Central PMCID: PMC5339239. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Haydar TF, Reeves RH. Trisomy 21 and early brain development. Trends Neurosci. 2012;35(2):81–91. doi: 10.1016/j.tins.2011.11.001 ; PubMed Central PMCID: PMC3273608. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Chakrabarti L, Best TK, Cramer NP, Carney RS, Isaac JT, Galdzicki Z, et al. Olig1 and Olig2 triplication causes developmental brain defects in Down syndrome. Nat Neurosci. 2010;13(8):927–934. doi: 10.1038/nn.2600 ; PubMed Central PMCID: PMC3249618. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Belichenko PV, Kleschevnikov AM, Masliah E, Wu C, Takimoto-Kimura R, Salehi A, et al. Excitatory-inhibitory relationship in the fascia dentata in the Ts65Dn mouse model of Down syndrome. J Comp Neurol. 2009;512(4):453–466. doi: 10.1002/cne.21895 . [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Kurt MA, Davies DC, Kidd M, Dierssen M, Florez J. Synaptic deficit in the temporal cortex of partial trisomy 16 (Ts65Dn) mice. Brain Res. 2000;858(1):191–197. doi: 10.1016/s0006-8993(00)01984-3 . [DOI] [PubMed] [Google Scholar]
- 34.Nosheny RL, Belichenko PV, Busse BL, Weissmiller AM, Dang V, Das D, et al. Increased cortical synaptic activation of TrkB and downstream signaling markers in a mouse model of Down Syndrome. Neurobiol Dis. 2015;77:173–190. Epub 2015/03/11. doi: 10.1016/j.nbd.2015.02.022 ; PubMed Central PMCID: PMC4689307. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Paul A, Crow M, Raudales R, He M, Gillis J, Huang ZJ. Transcriptional Architecture of Synaptic Communication Delineates GABAergic Neuron Identity. Cell. 2017;171(3):522–539 e20. Epub 2017/09/26. doi: 10.1016/j.cell.2017.08.032 ; PubMed Central PMCID: PMC5772785. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Salehi A, Delcroix JD, Belichenko PV, Zhan K, Wu C, Valletta JS, et al. Increased App expression in a mouse model of Down’s syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron. 2006;51(1):29–42. doi: 10.1016/j.neuron.2006.05.022 . [DOI] [PubMed] [Google Scholar]
- 37.Fuerst PG, Harris BS, Johnson KR, Burgess RW. A novel null allele of mouse DSCAM survives to adulthood on an inbred C3H background with reduced phenotypic variability. Genesis. 2010;48(10):578–584. doi: 10.1002/dvg.20662 ; PubMed Central PMCID: PMC2987671. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Schramm RD, Li S, Harris BS, Rounds RP, Burgess RW, Ytreberg FM, et al. A novel mouse Dscam mutation inhibits localization and shedding of DSCAM. PLoS ONE. 2012;7(12):e52652. doi: 10.1371/journal.pone.0052652 ; PubMed Central PMCID: PMC3530462. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.de Andrade GB, Long SS, Fleming H, Li W, Fuerst PG. DSCAM localization and function at the mouse cone synapse. J Comp Neurol. 2014;522(11):2609–2633. doi: 10.1002/cne.23552 ; PubMed Central PMCID: PMC4043867. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Tremblay R, Lee S, Rudy B. GABAergic Interneurons in the Neocortex: From Cellular Properties to Circuits. Neuron. 2016;91(2):260–292. Epub 2016/08/02. doi: 10.1016/j.neuron.2016.06.033 ; PubMed Central PMCID: PMC4980915. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Lim L, Mi D, Llorca A, Marin O. Development and Functional Diversification of Cortical Interneurons. Neuron. 2018;100(2):294–313. doi: 10.1016/j.neuron.2018.10.009 ; PubMed Central PMCID: PMC6290988. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Chini M, Hanganu-Opatz IL. Prefrontal Cortex Development in Health and Disease: Lessons from Rodents and Humans. Trends Neurosci. 2021;44(3):227–240. Epub 2020/11/29. doi: 10.1016/j.tins.2020.10.017 . [DOI] [PubMed] [Google Scholar]
- 43.Dieck ST, Sanmarti-Vila L, Langnaese K, Richter K, Kindler S, Soyke A, et al. Bassoon, a novel zinc-finger CAG/glutamine-repeat protein selectively localized at the active zone of presynaptic nerve terminals. J Cell Biol. 1998;142(2):499–509. doi: 10.1083/jcb.142.2.499 WOS:000075111300016. . [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Chaudhry FA, Reimer RJ, Bellocchio EE, Danbolt NC, Osen KK, Edwards RH, et al. The vesicular GABA transporter, VGAT, localizes to synaptic vesicles in sets of glycinergic as well as GABAergic neurons. J Neurosci. 1998;18(23):9733–9750. WOS:000077169800017. doi: 10.1523/JNEUROSCI.18-23-09733.1998 . [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Ye B, Liao D, Zhang X, Zhang P, Dong H, Huganir RL. GRASP-1: a neuronal RasGEF associated with the AMPA receptor/GRIP complex. Neuron. 2000;26(3):603–617. doi: 10.1016/s0896-6273(00)81198-8 . [DOI] [PubMed] [Google Scholar]
- 46.Del Pino I, Garcia-Frigola C, Dehorter N, Brotons-Mas JR, Alvarez-Salvado E, Martinez de Lagran M, et al. Erbb4 deletion from fast-spiking interneurons causes schizophrenia-like phenotypes. Neuron. 2013;79(6):1152–1168. doi: 10.1016/j.neuron.2013.07.010 . [DOI] [PubMed] [Google Scholar]
- 47.Fogarty M, Grist M, Gelman D, Marin O, Pachnis V, Kessaris N. Spatial genetic patterning of the embryonic neuroepithelium generates GABAergic interneuron diversity in the adult cortex. J Neurosci. 2007;27(41):10935–10946. Epub 2007/10/12. doi: 10.1523/JNEUROSCI.1629-07.2007 ; PubMed Central PMCID: PMC6672847. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Fuerst PG, Bruce F, Rounds RP, Erskine L, Burgess RW. Cell autonomy of DSCAM function in retinal development. Dev Biol. 2012;361(2):326–337. doi: 10.1016/j.ydbio.2011.10.028 ; PubMed Central PMCID: PMC3246579. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Sterne GR, Kim JH, Ye B. Dysregulated Dscam levels act through Abelson tyrosine kinase to enlarge presynaptic arbors. Elife. 2015;4:e05196. doi: 10.7554/eLife.05196 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Wang Y, Gupta A, Toledo-Rodriguez M, Wu CZ, Markram H. Anatomical, physiological, molecular and circuit properties of nest basket cells in the developing somatosensory cortex. Cereb Cortex. 2002;12(4):395–410. Epub 2002/03/09. doi: 10.1093/cercor/12.4.395 . [DOI] [PubMed] [Google Scholar]
- 51.Fazzari P, Paternain AV, Valiente M, Pla R, Lujan R, Lloyd K, et al. Control of cortical GABA circuitry development by Nrg1 and ErbB4 signalling. Nature. 2010;464(7293):1376–1380. doi: 10.1038/nature08928 . [DOI] [PubMed] [Google Scholar]
- 52.Tai Y, Janas JA, Wang CL, Van Aelst L. Regulation of chandelier cell cartridge and bouton development via DOCK7-mediated ErbB4 activation. Cell Rep. 2014;6(2):254–263. doi: 10.1016/j.celrep.2013.12.034 ; PubMed Central PMCID: PMC3920736. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Favuzzi E, Deogracias R, Marques-Smith A, Maeso P, Jezequel J, Exposito-Alonso D, et al. Distinct molecular programs regulate synapse specificity in cortical inhibitory circuits. Science (New York, NY). 2019;363(6425):413–417. Epub 2019/01/27. doi: 10.1126/science.aau8977 . [DOI] [PubMed] [Google Scholar]
- 54.Yang JM, Shen CJ, Chen XJ, Kong Y, Liu YS, Li XW, et al. erbb4 Deficits in Chandelier Cells of the Medial Prefrontal Cortex Confer Cognitive Dysfunctions: Implications for Schizophrenia. Cereb Cortex. 2018. doi: 10.1093/cercor/bhy316 . [DOI] [PubMed] [Google Scholar]
- 55.Blazquez-Llorca L, Woodruff A, Inan M, Anderson SA, Yuste R, DeFelipe J, et al. Spatial distribution of neurons innervated by chandelier cells. Brain Struct Funct. 2015;220(5):2817–2834. Epub 2014/07/25. doi: 10.1007/s00429-014-0828-3 ; PubMed Central PMCID: PMC4549388. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Szentagothai J. Module-Concept in Cerebral-Cortex Architecture. Brain Res. 1975;95(2–3):475–496. doi: 10.1016/0006-8993(75)90122-5 WOS:A1975AQ66500023. [DOI] [PubMed] [Google Scholar]
- 57.Jones EG. Varieties and distribution of non-pyramidal cells in the somatic sensory cortex of the squirrel monkey. J Comp Neurol. 1975;160(2):205–267. doi: 10.1002/cne.901600204 [DOI] [PubMed] [Google Scholar]
- 58.Taniguchi H, Lu J, Huang ZJ. The spatial and temporal origin of chandelier cells in mouse neocortex. Science (New York, NY). 2013;339(6115):70–74. doi: 10.1126/science.1227622 ; PubMed Central PMCID: PMC4017638. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Inan M, Anderson SA. The chandelier cell, form and function. Curr Opin Neurobiol. 2014;26:142–148. doi: 10.1016/j.conb.2014.01.009 ; PubMed Central PMCID: PMC4024324. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Javaherian A, Cline HT. Coordinated motor neuron axon growth and neuromuscular synaptogenesis are promoted by CPG15 in vivo. Neuron. 2005;45(4):505–512. doi: 10.1016/j.neuron.2004.12.051 . [DOI] [PubMed] [Google Scholar]
- 61.Larsen DD, Callaway EM. Development of layer-specific axonal arborizations in mouse primary somatosensory cortex. J Comp Neurol. 2006;494(3):398–414. doi: 10.1002/cne.20754 ; PubMed Central PMCID: PMC4651208. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Mayer C, Hafemeister C, Bandler RC, Machold R, Batista Brito R, Jaglin X, et al. Developmental diversification of cortical inhibitory interneurons. Nature. 2018;555(7697):457–462. doi: 10.1038/nature25999 ; PubMed Central PMCID: PMC6052457. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Mi D, Li Z, Lim L, Li M, Moissidis M, Yang Y, et al. Early emergence of cortical interneuron diversity in the mouse embryo. Science (New York, NY). 2018;360(6384):81–85. doi: 10.1126/science.aar6821 ; PubMed Central PMCID: PMC6195193. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Wang X, Tucciarone J, Jiang S, Yin F, Wang BS, Wang D, et al. Genetic Single Neuron Anatomy Reveals Fine Granularity of Cortical Axo-Axonic Cells. Cell Rep. 2019;26(11):3145–3159 e5. Epub 2019/03/14. doi: 10.1016/j.celrep.2019.02.040 . [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.DeFelipe J. Chandelier cells and epilepsy. Brain. 1999;122(Pt 10):1807–1822. doi: 10.1093/brain/122.10.1807 . [DOI] [PubMed] [Google Scholar]
- 66.Woo TU, Whitehead RE, Melchitzky DS, Lewis DA. A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia. Proc Natl Acad Sci U S A. 1998;95(9):5341–5346. doi: 10.1073/pnas.95.9.5341 ; PubMed Central PMCID: PMC20262. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Nakazawa K, Zsiros V, Jiang Z, Nakao K, Kolata S, Zhang S, et al. GABAergic interneuron origin of schizophrenia pathophysiology. Neuropharmacology. 2012;62(3):1574–1583. doi: 10.1016/j.neuropharm.2011.01.022 ; PubMed Central PMCID: PMC3090452. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Lewis DA, Curley AA, Glausier JR, Volk DW. Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci. 2012;35(1):57–67. Epub 2011/12/14. doi: 10.1016/j.tins.2011.10.004 ; PubMed Central PMCID: PMC3253230. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Lewis DA. Inhibitory neurons in human cortical circuits: substrate for cognitive dysfunction in schizophrenia. Curr Opin Neurobiol. 2014;26:22–26. Epub 2014/03/22. doi: 10.1016/j.conb.2013.11.003 ; PubMed Central PMCID: PMC4024332. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70.Tai Y, Gallo NB, Wang M, Yu JR, Van Aelst L. Axo-axonic Innervation of Neocortical Pyramidal Neurons by GABAergic Chandelier Cells Requires AnkyrinG-Associated L1CAM. Neuron. 2019;102(2):358–372 e9. Epub 2019/03/09. doi: 10.1016/j.neuron.2019.02.009 . [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71.Cline H, Haas K. The regulation of dendritic arbor development and plasticity by glutamatergic synaptic input: a review of the synaptotrophic hypothesis. J Physiol. 2008;586(6):1509–1517. doi: 10.1113/jphysiol.2007.150029 . [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Li W, Guan KL. The Down syndrome cell adhesion molecule (DSCAM) interacts with and activates Pak. J Biol Chem. 2004;279(31):32824–32831. Epub 2004/06/01. doi: 10.1074/jbc.M401878200 . [DOI] [PubMed] [Google Scholar]
- 73.Kamiyama D, McGorty R, Kamiyama R, Kim MD, Chiba A, Huang B. Specification of Dendritogenesis Site in Drosophila aCC Motoneuron by Membrane Enrichment of Pak1 through Dscam1. Dev Cell. 2015;35(1):93–106. doi: 10.1016/j.devcel.2015.09.007 WOS:000363076000013. . [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Schmucker D, Clemens JC, Shu H, Worby CA, Xiao J, Muda M, et al. Drosophila Dscam is an axon guidance receptor exhibiting extraordinary molecular diversity. Cell. 2000;101(6):671–684. Epub 2000/07/13. doi: 10.1016/s0092-8674(00)80878-8 . [DOI] [PubMed] [Google Scholar]
- 75.Wang TY, Guo H, Xiong B, Stessman HAF, Wu HD, Coe BP, et al. De novo genic mutations among a Chinese autism spectrum disorder cohort. Nat Commun. 2016;7. doi: 10.1038/ncomms13316 WOS:000387259000001. . [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76.Cellot G, Cherubini E. GABAergic signaling as therapeutic target for autism spectrum disorders. Front Pediatr. 2014;2. doi: 10.3389/fped.2014.00070 WOS:000209897200069. . [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77.Fuerst PG, Koizumi A, Masland RH, Burgess RW. Neurite arborization and mosaic spacing in the mouse retina require DSCAM. Nature. 2008;451(7177):470–U8. doi: 10.1038/nature06514 WOS:000252554100046. . [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78.Lu J, Tucciarone J, Padilla-Coreano N, He M, Gordon JA, Huang ZJ. Selective inhibitory control of pyramidal neuron ensembles and cortical subnetworks by chandelier cells. Nat Neurosci. 2017;20(10):1377–1383. Epub 2017/08/22. doi: 10.1038/nn.4624 ; PubMed Central PMCID: PMC5614838. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 79.Buffington SA, Sobotzik JM, Schultz C, Rasband MN. I kappa B alpha is not required for axon initial segment assembly. Mol Cell Neurosci. 2012;50(1):1–9. doi: 10.1016/j.mcn.2012.03.003 WOS:000305547700001. . [DOI] [PMC free article] [PubMed] [Google Scholar]
- 80.Yang B, Treweek JB, Kulkarni RP, Deverman BE, Chen CK, Lubeck E, et al. Single-Cell Phenotyping within Transparent Intact Tissue through Whole-Body Clearing. Cell. 2014;158(4):945–958. doi: 10.1016/j.cell.2014.07.017 WOS:000340944700022. . [DOI] [PMC free article] [PubMed] [Google Scholar]
- 81.Nelson AD, Caballero-Floran RN, Rodriguez Diaz JC, Hull JM, Yuan Y, Li J, et al. Ankyrin-G regulates forebrain connectivity and network synchronization via interaction with GABARAP. Mol Psychiatry. 2020;25(11):2800–2817. Epub 2018/12/07. doi: 10.1038/s41380-018-0308-x ; PubMed Central PMCID: PMC6542726. [DOI] [PMC free article] [PubMed] [Google Scholar]